FBXL13

Across TCGA pan-cancer cohorts, FBXL13 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FBXL13 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FBXL13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXL13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where FBXL13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.086	0.674	.004	16	view →
UCEC	DFS	Median	II,III,IV	0.928	0.436	.021	10	view →
SKCM	DFS	Median	All	0.914	0.714	.016	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
LUSC	DFS	Median	All	1.000	0.651	.016	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FBXL13–HNSC (OS)

Open the HNSC breakdown →